Welcome to our dedicated page for Cosciens Biopharma SEC filings (Ticker: CSCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The COSCIENS Biopharma Inc. (CSCI) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. COSCIENS files reports such as Form 20-F annual reports and Form 6-K current reports, which include financial statements, management’s discussion and analysis, and press releases on strategic initiatives, clinical programs and capital markets decisions.
Through these filings, investors can review how COSCIENS describes its business as a life sciences company focused on natural, plant-based active ingredients, cosmeceutical, nutraceutical and pharmaceutical products, and diagnostic assets like macimorelin (Macrilen; Ghryvelin) for adult growth hormone deficiency. The filings also discuss the company’s proprietary extraction technologies, its use of Pressurized Gas eXpanded (PGX) Technology, and the evolution of its portfolio following the merger of Aeterna Zentaris and Ceapro.
Key documents available or referenced via SEC filings include quarterly and interim financial statements, risk factor discussions, and detailed commentary on cost structure realignment, restructuring and zero-based budgeting initiatives. Filings also record important capital markets events, such as COSCIENS’ voluntary delisting from the Nasdaq Capital Market via Form 25, while retaining its Toronto Stock Exchange listing and seeking quotation for its shares in the U.S. over-the-counter market under the symbol CSCIF.
Stock Titan’s platform surfaces these filings alongside AI-powered summaries that explain complex sections, highlight changes from prior periods and point out items relevant to CSCI shareholders, such as discussions of Macrilen commercialization, PGX Technology scale-up and strategic program decisions. Users can quickly scan recent 6-K submissions, annual 20-F reports and other key documents to understand COSCIENS’ financial position, strategic direction and regulatory reporting history.
COSCIENS Biopharma Inc. is asking shareholders to approve a complex share capital change that will effectively cash out many small positions and allow the company to stop filing reports with the U.S. SEC. The plan combines a 1‑for‑150 consolidation with a 50‑for‑1 split. Holders with fewer than 150 shares in any registered position will be bought out for U.S.$1.60 per pre‑consolidation share, while others keep their stake and see their share count unchanged after the split. COSCIENS expects this to cut U.S. holders of record below 300, enabling a Form 15 filing and an estimated ~U.S.$1.9 million in annual cost savings, while its stock remains listed on the TSX and quoted on the OTCQB.
PETER PUCCETTI AND PUCCETTI FUNDS MANAGEMENT INC. have sharply reduced their reported stake in COSCIENS Biopharma Inc. to 15,687 common shares, representing about 0.5% of shares outstanding. This follows the sale of all of Puccetti’s indirect equity interest in Goodwood Inc., which managed Goodwood Fund.
Goodwood Fund previously held 241,570 COSCIENS shares that had been reported as beneficially owned by the reporting persons. After the transaction, Puccetti no longer owns or controls Goodwood, Goodwood Fund, or those shares, and a prior joint filing agreement among the parties has been terminated.
The filing confirms Puccetti’s remaining exposure is held indirectly through Puccetti Funds and that the group has ceased to beneficially own more than 5% of COSCIENS common stock, though Puccetti continues to serve as interim CEO and chair of the board.
COSCIENS Biopharma Inc. filed a report to share a press release responding to unusual trading in its shares. The company states it is not aware of any material undisclosed information that would explain the recent increase in trading volume and price of its common stock.
The filing also repeats extensive forward-looking statement cautions, highlighting risks tied to potential insolvency proceedings of its German subsidiaries, development and commercialization of its patented natural active ingredients, liquidity and capital resources, and internal controls. COSCIENS describes itself as a life science company focused on plant-based ingredients used in skincare products.
COSCIENS Biopharma Inc., a Canada-based company listed on the TSX and OTCQB, files its annual Form 20-F for the year ended December 31, 2025. The company had 3,183,330 Common Shares outstanding as of December 31, 2025.
COSCIENS focuses on oat-based cosmeceutical and nutraceutical ingredients (including oat beta-glucan and avenanthramides) and on commercializing its licensed PGX Technology for processing biopolymers into high-value materials. A large majority of current revenue comes from a single distribution partner, Symrise AG, under an exclusive supply and distribution agreement that runs to December 31, 2026.
The filing highlights substantial risk, including a disclosed substantial doubt about the company’s ability to continue as a going concern, heavy reliance on Symrise AG for over 84% of revenues, significant financing needs, and exposure to tariffs, raw-material supply disruptions and intense competition. COSCIENS is also managing insolvency proceedings for its German subsidiaries, which may lead to surrendering rights to Macrilen and potential non-cash accounting impacts. Additional risks include possible PFIC tax status for U.S. holders, volatility in its share price, potential TSX delisting, cybersecurity threats, environmental obligations, and prior material weaknesses in internal controls that the company reports as remediated in 2025.
COSCIENS Biopharma Inc. reported a smaller loss for 2025 while making significant strategic changes. Full-year revenue was $7.5 million, down from $9.6 million, but the net loss narrowed to $10.4 million from $15.3 million as operating expenses fell to $13.3 million from $23.0 million.
In Q4 2025, revenue declined to $1.8 million from $3.3 million, yet the quarterly net loss improved to $2.2 million from $6.7 million, driven mainly by lower R&D and impairment charges. Cash and cash equivalents were $7.3 million at December 31, 2025.
The company decided to stop funding its German subsidiaries that house its biopharmaceutical business, including Macrilen, and an insolvency application was filed in Germany. COSCIENS expects about $1.9 million in annualized cost savings and for the German subsidiaries’ liabilities, including $11.0 million of unfunded pension obligations, to drop from its future financial statements. It also plans to seek termination or suspension of its U.S. Exchange Act reporting while maintaining Canadian reporting and TSX/OTCQB listings.
COSCIENS Biopharma Inc. removed 10,190,859 registered common shares and related purchase rights from its Form F-1 registration by filing Post-Effective Amendment No. 6.
The amendment states the company terminated the offering under Registration Statement File No. 333-248561 and, consistent with its undertakings, is terminating effectiveness and removing any unsold securities. The original registration covered shares issuable on exercise of certain unregistered warrants exercisable through February 5, 2026 and August 3, 2025.
COSCIENS Biopharma Inc. terminates the Form F-1 offering that had registered up to 14,457,831 units with a proposed aggregate offering price of up to $12,000,000.
This Post-Effective Amendment No. 6 deregisters and removes from registration any unsold registered Units, Pre-Funded Units, Common Warrants, Placement Agent Warrants and the underlying Shares as of the amendment's effectiveness.